Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

被引：0
|
作者：
Johns, A. [1 ]
Eatock, M. [2 ]
Johal, S. [3 ]
机构：
[1] Pfizer UK, Tadworth, England
[2] No Ireland Canc Ctr, Belfast, Antrim, North Ireland
[3] RTI Hlth Solut, Sheffield, S Yorkshire, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
sunitinib; overall survival; cost-utility; pancreatic net;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：38 / 38
页数：1
相关论文
共 47 条
  • [21] The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate
    Raymond, E.
    Kulke, M. H.
    Qin, S.
    Yu, X.
    Schenker, M.
    Cubillo, A.
    Lou, W.
    Tomasek, J.
    This-Evensen, E.
    Fernandez, K.
    Rosbrook, B.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2017, 105 : 225 - 225
  • [22] Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China
    Wang, Yuhong
    Jin, Kaizhou
    Tan, Huangying
    Zhang, Pan
    Yang, Qiuchen
    Wang, Wei
    Li, Jie
    Shao, Chenghao
    Xue, Ling
    Feng, Shiting
    Chen, Minhu
    Yu, Xianjun
    Chen, Jie
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 507 - 516
  • [23] Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center
    Djihed, B.
    Alyda, M.
    Mohammed, O.
    NEUROENDOCRINOLOGY, 2017, 105 : 213 - 213
  • [24] Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors
    Gao, Heli
    Dong, Jia
    Zhang, Wuhu
    Xu, Huaxiang
    Ye, Longyun
    Li, Hao
    Ni, Quanxing
    Wang, Wenquan
    Liu, Liang
    ENDOCRINE PRACTICE, 2022, 28 (03) : 292 - 297
  • [25] Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations
    Liu, Eric
    Marincola, Paula
    Oberg, Kjell
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (05) : 412 - 419
  • [26] Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison
    Ishak, K. Jack
    Rael, Michael
    Hicks, Meagen
    Mittal, Sangeeta
    Eatock, Martin
    Valle, Juan W.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (10) : 947 - 958
  • [27] Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors
    Lee, Lingaku
    Ito, Tetsuhide
    Igarashi, Hisato
    Miki, Masami
    Fujimori, Nao
    Kawabe, Ken
    Jensen, Robert T.
    Ogawa, Yoshihiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 163 - 169
  • [28] Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors
    Lingaku Lee
    Tetsuhide Ito
    Hisato Igarashi
    Masami Miki
    Nao Fujimori
    Ken Kawabe
    Robert T. Jensen
    Yoshihiro Ogawa
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 163 - 169
  • [29] Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
    Angelousi, Anna
    Kamp, Kimberly
    Kaltsatou, Maria
    O'Toole, Dermot
    Kaltsas, Gregory
    de Herder, Wouter
    NEUROENDOCRINOLOGY, 2017, 105 (04) : 394 - 402
  • [30] Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
    Ito, Tetsuhide
    Tori, Masayuki
    Hashigaki, Satoshi
    Kimura, Nobuyuki
    Sato, Kazuo
    Ohki, Emiko
    Sawaki, Akira
    Okusaka, Takuji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) : 354 - 360
12345